Publications Update # 1

Date: 01-25-23

Ovarian Cancer

1. A must read paper comparing the genomic and immune landscape between the long-term survivors (~10 years) to those with short survival (~2 years). Short survival patient had much higher CCNE 1 mutation rates compared to those with long-term survival (much higher HRD mutations).

The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer - PubMed

Fewer than half of all patients with advanced-stage high-grade serous ovarian cancers (HGSCs) survive more than five years after diagnosis, but those who have an exceptionally long survival could provide insights into tumor biology and therapeutic approaches. We analyzed 60 patients with advanced-st…

PubMedDale W Garsed

2. Another paper discussing the role of High-level Amplification of CCNE1 (~9% of  all HGSOC patients) and its association with worse survival.

CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study - PubMed

This study provides large-scale validation that CCNE1 high-level amplification is associated with shorter survival, supporting its utility as a prognostic biomarker in HGSC.

PubMedEun-Young Kang

3. This phase II trial investigated Adavosertib in tumors with CCNE1 amplification. From the abstract:

Fourteen patients with epithelial ovarian cancer showed an ORR of 36% (95% CI, 13 to 65) and SD ≥ 6 months/PR of 57% (95% CI, 29 to 82), a median progression-free survival duration of 6.3 months (95% CI, 2.4 to 10.2), and a median overall survival duration of 14.9 months (95% CI, 8.9 to 20.9).

Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification - PubMed

Adavosertib monotherapy demonstrates a manageable toxicity profile and promising clinical activity in refractory solid tumors harboring <i>CCNE1</i> amplification, especially in epithelial ovarian cancer. Further study of adavosertib, alone or in combination with other therapeutic agents, in <i>CCNE…

PubMedSiqing Fu